CAS.NO: 116094-23-6
Insulin Aspart is a biosynthetic fast-acting human insulin analog by substituting aspartic acid for proline at position 28 of the B chain of human insulin, which can significantly reduce postprandial blood glucose in the treatment of typeⅠand typeⅡ diabetes, and the risk of hypoglycemia, especially nighttime hypoglycemia, is significantly reduced.
| Product Name | Insulin Aspart |
| Packing Specification | 10g/100g/500g |
| Appearances | White or off-white powder |
| Activity | NLT 15Unit/mg |
| Content | 95.0%~105.0% |
| Bacterial Endotoxin | Less than 10 EU/mg |
| Residual HCP | NMT 10ng/mg |
| Residual Exogenous DNA | NMT 10ng/dose |
| Macromolecular Potein | NMT 0.5% |
| HPLC Purity | ＞99.0% |
| Storage Conditions | -15℃ below, protected from light, sealed. |
The data should be subject to test report of products.
Insulin Aspart easy dissolved in acidic (pH<2.5), neutral and alkaline conditions, and can be dissolved and clarified above pH7.0.
Transportation stability: It is transported in an ice pack to keep it active。
Storage stability: The fast acting Insulin Aspart can be stored for at least 24 months at -15°C below.
Pollution should be avoided during operation.
The product should not be used for diagnosis or treatment of animals or humans.
